Overview

Safety and Suitability of Supplementing Early MIP Surgery (MIPS) of ICH With Pioglitazone

Status:
Not yet recruiting
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
This is an exploratory single-center prospective study of 20 subjects with primary basal ganglia ICH who will receive early MIPS in combination with perioperative pioglitazone treatment. Outcomes will be compared to matched subjects with basal ganglia ICH who undergo MIPS alone as part of the ENRICH trial. This study will take approximately two years to complete.
Phase:
Phase 2
Details
Lead Sponsor:
University of Maryland, Baltimore
Collaborator:
Nico Corporation
Treatments:
Pioglitazone